The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma
Copyright©2019. The Korean Academy of Tuberculosis and Respiratory Diseases..
BACKGROUND: Docetaxel is one of the standard treatments for advanced non-small cell lung cancer. Docetaxel is usually administered in a 3-week schedule, but there is significant toxicity. In this phase II clinical study, we investigated the efficacy and safety of a 4-weekly schedule of docetaxel monotherapy, as first-line chemotherapy for advanced squamous cell carcinoma in elderly lung cancer patients.
METHODS: Patients with stage IIIB/ IV lung squamous-cell carcinoma age 70 or older, that had not undergone cytotoxic chemotherapy were enrolled. Patients received docetaxel 25 mg/m² on days 1, 8, and 15, every 4 weeks. Primary endpoint was the objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity profiles.
RESULTS: A total of 19 patients were enrolled. Among 19 patients, 17 were for evaluated efficacy and safety. In the intent-to-treat population, ORR and disease control rate (DCR) were 11.8% and 47.1%, respectively. In the response evaluable population, ORR was 16.7% and DCR was 66.7%. Median PFS and OS were 3.1 months and 3.3 months, respectively. There were three adverse grade 3/4 events. Grade 1 neutropenia was reported in one patient.
CONCLUSION: Our data failed to demonstrate efficacy of a 4-weekly docetaxel regimen, in elderly patients with a poor performance status. However, incidence of side effects, including neutropenia, was lower than with a 3-week docetaxel regimen, as previously reported.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:82 |
|---|---|
| Enthalten in: |
Tuberculosis and respiratory diseases - 82(2019), 3 vom: 29. Juli, Seite 211-216 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Choi, Jong Hyun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aged |
|---|
| Anmerkungen: |
Date Revised 01.10.2020 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4046/trd.2018.0019 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM294650377 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM294650377 | ||
| 003 | DE-627 | ||
| 005 | 20231225081940.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4046/trd.2018.0019 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0982.xml |
| 035 | |a (DE-627)NLM294650377 | ||
| 035 | |a (NLM)30841020 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Choi, Jong Hyun |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.10.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright©2019. The Korean Academy of Tuberculosis and Respiratory Diseases. | ||
| 520 | |a BACKGROUND: Docetaxel is one of the standard treatments for advanced non-small cell lung cancer. Docetaxel is usually administered in a 3-week schedule, but there is significant toxicity. In this phase II clinical study, we investigated the efficacy and safety of a 4-weekly schedule of docetaxel monotherapy, as first-line chemotherapy for advanced squamous cell carcinoma in elderly lung cancer patients | ||
| 520 | |a METHODS: Patients with stage IIIB/ IV lung squamous-cell carcinoma age 70 or older, that had not undergone cytotoxic chemotherapy were enrolled. Patients received docetaxel 25 mg/m² on days 1, 8, and 15, every 4 weeks. Primary endpoint was the objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity profiles | ||
| 520 | |a RESULTS: A total of 19 patients were enrolled. Among 19 patients, 17 were for evaluated efficacy and safety. In the intent-to-treat population, ORR and disease control rate (DCR) were 11.8% and 47.1%, respectively. In the response evaluable population, ORR was 16.7% and DCR was 66.7%. Median PFS and OS were 3.1 months and 3.3 months, respectively. There were three adverse grade 3/4 events. Grade 1 neutropenia was reported in one patient | ||
| 520 | |a CONCLUSION: Our data failed to demonstrate efficacy of a 4-weekly docetaxel regimen, in elderly patients with a poor performance status. However, incidence of side effects, including neutropenia, was lower than with a 3-week docetaxel regimen, as previously reported | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Aged | |
| 650 | 4 | |a Carcinoma, Non-Small-Cell Lung | |
| 650 | 4 | |a Carcinoma, Squamous Cell | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Docetaxel | |
| 650 | 4 | |a Lung Neoplasms | |
| 650 | 4 | |a Safety | |
| 650 | 4 | |a Therapeutics | |
| 650 | 4 | |a Treatment Outcome | |
| 700 | 1 | |a Choi, Juwhan |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Sang Mi |e verfasserin |4 aut | |
| 700 | 1 | |a Oh, Jee Youn |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Young Seok |e verfasserin |4 aut | |
| 700 | 1 | |a Min, Kyung Hoon |e verfasserin |4 aut | |
| 700 | 1 | |a Hur, Gyu Young |e verfasserin |4 aut | |
| 700 | 1 | |a Shim, Jae Jeong |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Kyung Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Hyun Kyung |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Sung Yong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Tuberculosis and respiratory diseases |d 2012 |g 82(2019), 3 vom: 29. Juli, Seite 211-216 |w (DE-627)NLM222134194 |x 1738-3536 |7 nnns |
| 773 | 1 | 8 | |g volume:82 |g year:2019 |g number:3 |g day:29 |g month:07 |g pages:211-216 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4046/trd.2018.0019 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 82 |j 2019 |e 3 |b 29 |c 07 |h 211-216 | ||